What is TB-500?

A naturally occurring protein of 43 amino acids, present in most human cells and one of the more abundant proteins in the body. Its principal characterised function is binding actin — the protein that forms the cell's internal scaffolding and drives cell movement.

By sequestering actin monomers, it participates in regulating how quickly cells can reorganise their internal structure, which is why it turns up in research on cell migration, wound repair and tissue remodelling.

A much shorter synthetic peptide corresponding to a region of thymosin beta-4 identified as carrying much of the actin-binding activity. It is a fragment, synthesised on its own, not the intact protein.

The reasoning behind isolating it is ordinary drug-discovery logic — find the active region, make just that, get a smaller and cheaper molecule. Whether the fragment reproduces the parent protein's behaviour is exactly the question such a programme exists to answer, and for TB-500 it has not been answered in humans.

Because the two literatures are very different in size and quality, and citations move freely between them. Work on full-length thymosin beta-4 is the larger, better-established body, including some clinical investigation in specific indications. Work specifically on TB-500 as a distinct entity is considerably thinner and largely preclinical.

The practical consequence: when you read a confident claim about TB-500, check which molecule the underlying study actually used. It is frequently not the one the citing article implies.

Predominantly injury and tissue-repair endpoints in animal models, alongside in vitro work relating to cell migration and new blood vessel formation. The reported outcomes are the source of its reputation for accelerating recovery.

The body of work specific to the fragment rather than the parent protein is comparatively thin, and much of what circulates as evidence for TB-500 is in fact evidence about thymosin beta-4.

Not in any established sense. There is no substantial randomised controlled trial evidence in people demonstrating efficacy for a defined indication, and no long-term human safety data.

Full-length thymosin beta-4 has seen some clinical investigation, which is a genuinely different situation — and is precisely why the conflation matters so much. The stronger evidence attaches to the molecule that is not being sold.

Actin sequestration is the anchor: by binding actin monomers, the parent protein influences how cells reorganise and migrate, which is relevant to wound closure and tissue remodelling. Downstream effects on angiogenesis and inflammatory signalling are also discussed.

As with any preclinical mechanism, describing a plausible pathway is a different achievement from demonstrating a clinical outcome. The gap between the two is the trial evidence that does not exist here.

No. There is no approved TB-500 product anywhere in the major jurisdictions, which means no approved indication, no prescribing information, and no regulated manufacturing standard for a product intended for people.

Without manufacturing oversight there is no independent verification that a given vial contains what the label says, in the quantity stated, free of contaminants.

Yes, at all times — in competition and out of it — for any athlete subject to anti-doping testing. It falls under the prohibited non-approved substances category, which covers compounds with no human regulatory approval.

Testing methods for peptides of this kind exist and detection windows are not necessarily short, so the practical risk is not limited to the period immediately after administration.

It has been the subject of enforcement action in horse racing, where regulators have treated it as a prohibited substance and pursued cases involving its use.

That history is worth knowing because it is often the most concrete regulatory record available for a compound with no human approval — the enforcement happened somewhere, just not in a human clinical context.

Applying the five-half-lives convention to its reported half-life puts clearance within a day. On any multi-day interval, each administration has cleared entirely before the next arrives.

There is therefore no accumulation and no plateau. The curve is a series of independent spikes rather than a rising baseline, which is a fundamentally different shape from a weekly compound's.

Any argument for intervals measured in days has to rest on downstream effects outlasting the molecule — a process initiated and then continuing after clearance — rather than on the compound remaining present.

That is not an unreasonable proposition in principle; tissue remodelling genuinely does run on its own timeline. But it is a proposition, and for a compound without human efficacy data it is not one the evidence settles.

From overlap in what their respective animal literatures examine — both have been studied in tissue-repair models — combined with online communities converging on a shared nickname and a shared recommendation.

It spread as a convention rather than as a conclusion, and conventions of that kind acquire authority through repetition rather than evidence.

There is no established human evidence that combining them produces an additive or synergistic result. That claim is an extrapolation from separate preclinical work on each compound, which is a weaker inference than it usually sounds.

Their pharmacokinetics also differ, which is a separate practical point from whether either does anything in humans — two compounds with different clearance profiles are not straightforwardly 'run together' even in principle.